Cash from Operations (Quarterly) Chart

Historical Cash from Operations (Quarterly) Data

View and export this data back to 2011. Start Trial.
Date Value
September 30, 2026 7.606B
June 30, 2026 3.436B
March 31, 2026 3.829B
December 31, 2025 5.218B
September 30, 2025 7.024B
June 30, 2025 5.153B
March 31, 2025 1.635B
December 31, 2024 7.048B
September 30, 2024 5.447B
June 30, 2024 2.271B
March 31, 2024 4.04B
December 31, 2023 4.715B
September 30, 2023 7.574B
June 30, 2023 6.319B
March 31, 2023 4.193B
December 31, 2022 7.428B
September 30, 2022 7.602B
June 30, 2022 5.005B
March 31, 2022 4.908B
December 31, 2021 5.075B
September 30, 2021 7.935B
June 30, 2021 4.89B
March 31, 2021 4.877B
December 31, 2020 4.854B
September 30, 2020 5.83B
Date Value
June 30, 2020 3.089B
March 31, 2020 3.815B
December 31, 2019 3.275B
September 30, 2019 4.726B
June 30, 2019 2.306B
March 31, 2019 3.017B
December 31, 2018 3.392B
September 30, 2018 4.524B
June 30, 2018 2.866B
March 31, 2018 2.645B
December 31, 2017 2.584B
September 30, 2017 3.271B
June 30, 2017 2.003B
March 31, 2017 2.102B
December 31, 2016 1.541B
September 30, 2016 1.454B
June 30, 2016 1.918B
March 31, 2016 2.128B
December 31, 2015 1.963B
September 30, 2015 2.155B
June 30, 2015 1.832B
March 31, 2015 1.585B
December 31, 2014 -578.00M
September 30, 2014 1.786B
June 30, 2014 1.717B

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
Gilead Sciences, Inc. 5.035B
Regeneron Pharmaceuticals, Inc. 1.783B
Biogen, Inc. 640.80M
Amgen, Inc. 4.241B
REGENXBIO, Inc. 38.61M